# A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC

> **NCT03793725** · PHASE2 · UNKNOWN · sponsor: **Yanqiao Zhang** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** SHR1210
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT03793725
- **Lead sponsor:** Yanqiao Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-30
- **Primary completion:** 2020-01-30
- **Final completion:** 2021-01-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-01-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03793725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03793725, "A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03793725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*